{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:06:34Z","timestamp":1789977994748,"version":"4.0.1"},"reference-count":34,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Head &amp; Neck"],"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n This study was aimed to assess the efficacy and potential role of laryngeal function preservation of toripalimab combined with TPF in locally advanced hypopharyngeal squamous cell carcinoma (LA HSCC) patients.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Patients with histologically confirmed LA HSCC received three cycles of toripalimab combined with TPF as induction chemoimmunotherapy (I\u2010CI) in this single\u2010arm phase II study. The primary endpoint was the CR rate at 3\u2010months after definitive local treatment.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 29 enrolled patients (62.1% N3b), CR rate was 80.0% (16\/20) among the non\u2010surgical patients and 100% (9\/9) surgical patients maintained disease\u2010free, at 3\u2010month after definitive local treatment. The CR rate for the cohort was 86.2% (25\/29). The laryngeal\u2010preservation rate was 86.2% (25\/29). Overall response rate of I\u2010CI was 81.5%. With a median follow\u2010up of 38.3\u2009months, the 3\u2010year progression\u2010free survival rate, overall survival, and larynx preservation survival were 64.0%, 76.3%, and 68.8%, respectively.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Toripalimab combined with TPF showed encouraging efficacy, promising larynx preservation and acceptable toxicity in this cohort of LA HSCC.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/hed.70417","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:35:55Z","timestamp":1789976155000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toripalimab Plus\n TPF<\/scp>\n as Induction Chemoimmunotherapy for the Treatment of Locally Advanced Hypopharyngeal Carcinoma: A Prospective Phase\n II<\/scp>\n Study"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6154-2191","authenticated-orcid":false,"given":"Dan","family":"Zhao","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Radiation Oncology Peking University Cancer Hospital & Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5027-0725","authenticated-orcid":false,"given":"Meng","family":"Wan","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Radiation Oncology Peking University Cancer Hospital & Institute Beijing China"},{"name":"Radiation Oncology Department, Beijing Obstetrics and Gynecology Hospital Capital Medical University\/Beijing Maternal and Child Health Care Hospital Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3595-947X","authenticated-orcid":false,"given":"Xiaolong","family":"Xu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Radiation Oncology Peking University Cancer Hospital & Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0910-9718","authenticated-orcid":false,"given":"Zhou","family":"Huang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Radiation Oncology Peking University Cancer Hospital & Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixin","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Radiation Oncology Peking University Cancer Hospital & Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4603-0684","authenticated-orcid":false,"given":"Baomin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Radiation Oncology Peking University Cancer Hospital & Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3440-2472","authenticated-orcid":false,"given":"Shaowen","family":"Xiao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Radiation Oncology Peking University Cancer Hospital & Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-1057","authenticated-orcid":false,"given":"Shunyu","family":"Gao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Radiology Peking University Cancer Hospital & Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7634-282X","authenticated-orcid":false,"given":"Yanhua","family":"Bai","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Pathology Peking University Cancer Hospital & Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0718-4355","authenticated-orcid":false,"given":"Tianxiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Head and Neck Surgery Peking University Cancer Hospital & Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-7558","authenticated-orcid":false,"given":"Yuntao","family":"Song","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Head and Neck Surgery Peking University Cancer Hospital & Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1624-2181","authenticated-orcid":false,"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Head and Neck Surgery Peking University Cancer Hospital & Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9219-7195","authenticated-orcid":false,"given":"Yan","family":"Sun","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Radiation Oncology Peking University Cancer Hospital & Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"3","key":"e_1_2_12_2_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray F.","year":"2024","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"1","key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and Neck Cancer","volume":"382","author":"Chow L. Q. M.","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","article-title":"Long\u2010Term Results of RTOG 91\u201011: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer","volume":"31","author":"Forastiere A. A.","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdy102","article-title":"Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Role, Controversy, and Future Directions","volume":"29","author":"Haddad R. I.","year":"2018","journal-title":"Annals of Oncology"},{"issue":"5","key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(21)00076-0","article-title":"Chemotherapy and Radiotherapy in Locally Advanced Head and Neck Cancer: An Individual Patient Data Network Meta\u2010Analysis","volume":"22","author":"Petit C.","year":"2021","journal-title":"Lancet Oncology"},{"issue":"19","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous\u2010Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris R. L.","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"10167","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic Head\u2010And\u2010Neck Squamous Cell Carcinoma (KEYNOTE\u2010040): A Randomised, Open\u2010Label, Phase 3 Study","volume":"393","author":"Cohen E. E. W.","year":"2019","journal-title":"Lancet"},{"issue":"10212","key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab Alone or With Chemotherapy Versus Cetuximab With Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE\u2010048): A Randomised, Open\u2010Label, Phase 3 Study","volume":"394","author":"Burtness B.","year":"2019","journal-title":"Lancet"},{"issue":"20","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER\u201002 Randomized Clinical Trial","volume":"330","author":"Mai H. Q.","year":"2023","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s13046-022-02510-2","article-title":"Neoadjuvant Toripalimab Combined With Gemcitabine and Cisplatin in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (NeoTGP01): An Open Label, Single\u2010Arm, Phase Ib Clinical Trial","volume":"41","author":"Huang X.","year":"2022","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"1571776","DOI":"10.3389\/fonc.2025.1571776","article-title":"Neoadjuvant Toripalimab Combined With Chemotherapy in Locally Advanced HNSCC","volume":"15","author":"Wang Z.","year":"2025","journal-title":"Frontiers in Oncology"},{"issue":"5","key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1016\/S1470-2045(25)00020-8","article-title":"International Consensus on Laryngeal Preservation Strategies in Laryngeal and Hypopharyngeal Cancer","volume":"26","author":"Ferrari M.","year":"2025","journal-title":"Lancet Oncology"},{"issue":"17","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer","volume":"357","author":"Vermorken J. B.","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1200\/JCO.2012.42.3988","article-title":"Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study","volume":"31","author":"Lefebvre J. L.","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2739\/kurumemedj.MS65003","article-title":"Definitive Radiotherapy Following Induction Chemotherapy for Hypopharyngeal Cancer: Selecting Candidates for Organ\u2010Preserving Treatment Based on the Response to Induction Chemotherapy","volume":"62","author":"Yanagi T.","year":"2015","journal-title":"Kurume Medical Journal"},{"issue":"2","key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(10)70279-5","article-title":"Induction Chemotherapy With Cisplatin and Fluorouracil Alone or in Combination With Docetaxel in Locally Advanced Squamous\u2010Cell Cancer of the Head and Neck: Long\u2010Term Results of the TAX 324 Randomised Phase 3 Trial","volume":"12","author":"Lorch J. H.","year":"2011","journal-title":"Lancet Oncology"},{"issue":"4","key":"e_1_2_12_18_1","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv368","article-title":"Long\u2010Term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5\u2010Fluorouracil, \u00b1 Docetaxel for Larynx Preservation","volume":"108","author":"Janoray G.","year":"2016","journal-title":"JNCI Journal of the National Cancer Institute"},{"issue":"19","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus\u2013Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial","volume":"26","author":"Uppaluri R.","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.62347\/HVRH6856","article-title":"Efficacy and Toxicity of PD\u20101 Inhibitor Combined With Induction Chemotherapy for Locally Advanced Laryngeal and Hypopharyngeal Cancers","volume":"15","author":"Zhao T.","year":"2025","journal-title":"American Journal of Cancer Research"},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"1364799","DOI":"10.3389\/fimmu.2024.1364799","article-title":"Neoadjuvant Therapy With Chemotherapy and Immune Checkpoint Inhibitor for Laryngeal Function Preservation in Locally Advanced Hypopharyngeal Cancer","volume":"15","author":"Wu S. G.","year":"2024","journal-title":"Frontiers in Immunology"},{"key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"113197","DOI":"10.1016\/j.intimp.2024.113197","article-title":"Neoadjuvant Chemoimmunotherapy for Laryngeal Preservation in Locally Advanced Hypopharyngeal Cancer","volume":"142","author":"Pan Y.","year":"2024","journal-title":"International Immunopharmacology"},{"issue":"3","key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00262-023-03579-0","article-title":"Retrospective Assessment of Neoadjuvant Camrelizumab Combined With Induction Chemotherapy: Efficacy in Laryngeal Preservation for Advanced Hypopharyngeal and Laryngeal Squamous Cell Carcinoma","volume":"73","author":"Peng J.","year":"2024","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"12","key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1007\/s00262-023-03550-z","article-title":"PD\u20101 Inhibitors Combined With Paclitaxel (Albumin\u2010Bound) and Cisplatin for Larynx Preservation in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma: A Retrospective Study","volume":"72","author":"Fang Q.","year":"2023","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"16","key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1200\/JCO.2023.41.16_suppl.6077","article-title":"Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma: A Single\u2010Arm Phase 2 Clinical Trial","volume":"41","author":"Chen Y.","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1158\/1078-0432.CCR-23-2398","article-title":"Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single\u2010Arm Phase II Clinical Trial","volume":"30","author":"Ou X.","year":"2024","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1038\/s41467-024-49121-3","article-title":"Camrelizumab\u2010Based Induction Chemoimmunotherapy in Locally Advanced Stage Hypopharyngeal Carcinoma: Phase II Clinical Trial","volume":"15","author":"Gong H.","year":"2024","journal-title":"Nature Communications"},{"issue":"16","key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1200\/JCO.2023.41.16_suppl.6070","article-title":"Induction Therapy of Toripalimab Combined With Docetaxel and Cisplatin in Locally Advanced Hypopharyngeal Squamous Cell Carcinoma (HPSCC): A Single\u2010Arm, Phase II Clinical Trial","volume":"41","author":"Bai C.","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"105505","DOI":"10.1016\/j.esmoop.2025.105505","article-title":"Tislelizumab Plus Nab\u2010Paclitaxel and Cisplatin as Induction Immunochemotherapy for Organ Preservation of Locally Advanced Hypopharyngeal Squamous Cell Carcinoma: A Single\u2010Arm Phase II Trial","volume":"10","author":"Gui L.","year":"2025","journal-title":"ESMO Open"},{"key":"e_1_2_12_30_1","doi-asserted-by":"crossref","first-page":"107007","DOI":"10.1016\/j.oraloncology.2024.107007","article-title":"The Prognostic Value of Image\u2010Identified Extranodal Extension in Laryngeal and Hypopharyngeal Carcinoma Following Definitive (Chemo\u2010)radiotherapy","volume":"158","author":"Alsheikh S.","year":"2024","journal-title":"Oral Oncology"},{"issue":"2","key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/hed.27978","article-title":"The Prognostic Importance of Radiologic Extranodal Extension in Hypopharyngeal Carcinoma","volume":"47","author":"Liao Y.","year":"2025","journal-title":"Head & Neck"},{"issue":"4","key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0016-5085(19)34983-2","article-title":"Colonic Histologic Changes Induced by 5\u2010Fluorouracil","volume":"43","author":"Milles S. S.","year":"1962","journal-title":"Gastroenterology"},{"issue":"6","key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1097\/SLA.0000000000004564","article-title":"Multicenter Randomized Phase 2 Trial Comparing Chemoradiotherapy and Docetaxel Plus 5\u2010Fluorouracil and Cisplatin Chemotherapy as Initial Induction Therapy for Subsequent Conversion Surgery in Patients With Clinical T4b Esophageal Cancer: Short\u2010Term Results","volume":"274","author":"Sugimura K.","year":"2021","journal-title":"Annals of Surgery"},{"key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"800879","DOI":"10.3389\/fimmu.2021.800879","article-title":"Immune Checkpoint Inhibitor\u2010Associated Colitis: From Mechanism to Management","volume":"12","author":"Tang L.","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"e000173","DOI":"10.1136\/jitc-2019-000173","article-title":"Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor\u2010Positive, HER2\u2212Negative Endocrine\u2010Refractory Metastatic Breast Cancer","volume":"8","author":"Shah A. N.","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"}],"container-title":["Head & Neck"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.70417","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hed.70417","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.70417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:35:59Z","timestamp":1789976159000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hed.70417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":34,"alternative-id":["10.1002\/hed.70417"],"URL":"https:\/\/doi.org\/10.1002\/hed.70417","archive":["Portico"],"relation":{},"ISSN":["1043-3074","1097-0347"],"issn-type":[{"value":"1043-3074","type":"print"},{"value":"1097-0347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"2026-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"hed.70417"}}